1. Home
  2. TLSI vs ELA Comparison

TLSI vs ELA Comparison

Compare TLSI & ELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TLSI
  • ELA
  • Stock Information
  • Founded
  • TLSI 2010
  • ELA 1965
  • Country
  • TLSI United States
  • ELA United States
  • Employees
  • TLSI N/A
  • ELA N/A
  • Industry
  • TLSI Medical Specialities
  • ELA Consumer Specialties
  • Sector
  • TLSI Health Care
  • ELA Consumer Discretionary
  • Exchange
  • TLSI Nasdaq
  • ELA Nasdaq
  • Market Cap
  • TLSI 160.4M
  • ELA 156.2M
  • IPO Year
  • TLSI N/A
  • ELA N/A
  • Fundamental
  • Price
  • TLSI $5.19
  • ELA $6.49
  • Analyst Decision
  • TLSI Strong Buy
  • ELA Strong Buy
  • Analyst Count
  • TLSI 6
  • ELA 1
  • Target Price
  • TLSI $11.75
  • ELA $9.00
  • AVG Volume (30 Days)
  • TLSI 34.3K
  • ELA 17.2K
  • Earning Date
  • TLSI 05-14-2025
  • ELA 05-07-2025
  • Dividend Yield
  • TLSI N/A
  • ELA N/A
  • EPS Growth
  • TLSI N/A
  • ELA 15.15
  • EPS
  • TLSI N/A
  • ELA 0.28
  • Revenue
  • TLSI $29,431,000.00
  • ELA $188,774,278.00
  • Revenue This Year
  • TLSI $56.00
  • ELA $6.47
  • Revenue Next Year
  • TLSI $52.17
  • ELA $7.42
  • P/E Ratio
  • TLSI N/A
  • ELA $22.69
  • Revenue Growth
  • TLSI 58.99
  • ELA 14.19
  • 52 Week Low
  • TLSI $3.50
  • ELA $4.20
  • 52 Week High
  • TLSI $10.24
  • ELA $7.88
  • Technical
  • Relative Strength Index (RSI)
  • TLSI 40.35
  • ELA 51.30
  • Support Level
  • TLSI $4.66
  • ELA $6.35
  • Resistance Level
  • TLSI $5.35
  • ELA $6.99
  • Average True Range (ATR)
  • TLSI 0.37
  • ELA 0.32
  • MACD
  • TLSI -0.05
  • ELA -0.00
  • Stochastic Oscillator
  • TLSI 43.44
  • ELA 53.24

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

About ELA Envela Corporation

Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.

Share on Social Networks: